| Theme | IPMN/Pancreatic Cyst as an Increasing Common Disease -- Current Status and Issues | |
|---|---|---|
| Title | Revised Points of the International Consensus Guidelines 2017 for the Management of Intraductal Papillary Mucinous Neoplasm of the Pancreas | |
| Publish Date | 2019/11 | |
| Author | Yusuke Watanabe | Department of Surgery and Oncology, Graduate School of Medical Sciences, Kyushu University |
| Author | Takao Ohtsuka | Department of Surgery and Oncology, Graduate School of Medical Sciences, Kyushu University |
| Author | Yasuhisa Mori | Department of Surgery and Oncology, Graduate School of Medical Sciences, Kyushu University |
| Author | Naoki Ikenaga | Department of Surgery and Oncology, Graduate School of Medical Sciences, Kyushu University |
| Author | Kohei Nakata | Department of Surgery and Oncology, Graduate School of Medical Sciences, Kyushu University |
| Author | Masafumi Nakamura | Department of Surgery and Oncology, Graduate School of Medical Sciences, Kyushu University |
| [ Summary ] | The International association of pancreatology (IAP) published the revision of international consensus guidelines for the management of intraductal papillary mucinous neoplasm (IPMN) in 2017. In the revised guidelines, several alterations were made in surgical indication and surveillance strategies. The main alteration in surgical indication was the introduction of the mural nodule size as a predictive factor and recommendations became more practical and conservative. Regarding the surveillance strategy for non‒resected IPMN, the intervals of surveillance according to the size stratification were mentioned more in detail. However, this strategy did not take into account the risk of the metachronous development of concomitant pancreatic ductal adenocarcinoma during surveillance for IPMN without resection. This review article discusses the surgical indication and surveillance strategies for IPMN advocated by the 2017 revised international consensus guidelines. Moreover, international guidelines for the management of IPMN advocated by the European Study Group on Cystic Tumors of the Pancreas and American Gastroenterological Association were introduced and compared with the 2017 revised international consensus guidelines advocated by IAP. | |